Literature DB >> 21382184

Relative efficacy of different MRI signs in diagnosing active Crohn's disease, compared against a histological gold standard.

Arian Lasocki1, Alexander Pitman, Richard Williams, Belinda Lui, Andrius V Kalade, Stephen Farish.   

Abstract

INTRODUCTION: There has been growing interest in the use of MRI in assessing Crohn's disease because of its lack of ionising radiation. Many MRI signs have been described in the literature, but their relative utility is unknown.
METHODS: The MRIs of the bowel performed at 1.5 Tesla were blindly reviewed on 26 patients with recent histology (surgery and/or colonoscopy and their associated reports) according to a dedicated pro forma. Each patient's bowel was divided into nine segments. Each segment was assessed as to the presence or absence of 15 MRI signs described in the literature: abnormal gadolinium enhancement (both subjective and objective), wall oedema, fat oedema, fat proliferation, nodal enlargement, free fluid, wall nodularity, serosal blurring, mural thickening >4 mm, stricture, multi-segmental disease, fistula, abscess and layered contrast enhancement. The results were compared against a histological gold standard with a six-point scale of disease severity. RESULTS AND
CONCLUSIONS: MRI correctly identified all 15 patients with at least established mucosal disease, and three of eight with only mild mucosal disease. Combining these results, a positive MRI correlated highly with at least early mucosal disease (positive predictive value 95%), while the presence of established mucosal disease was unlikely if MRI was negative (negative predictive value 100%). The MRI signs found to be the most sensitive for detecting active Crohn's disease were those related to the bowel wall, namely, wall thickening, nodularity, contrast enhancement and oedema. The most specific signs were the presence of multi-segmental disease, layered contrast enhancement and complications (fistula and abscess).
© 2011 The Authors. Journal of Medical Imaging and Radiation Oncology © 2011 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Year:  2011        PMID: 21382184     DOI: 10.1111/j.1754-9485.2010.02223.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  6 in total

1.  Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin.

Authors:  Jesica C Makanyanga; Doug Pendsé; Nikolaos Dikaios; Stuart Bloom; Sara McCartney; Emma Helbren; Elaine Atkins; Terry Cuthbertson; Shonit Punwani; Alastair Forbes; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2013-09-12       Impact factor: 5.315

2.  Small bowel enteroclysis with magnetic resonance imaging and computed tomography in patients with failed and uncertain passage of a patency capsule.

Authors:  Frans-Thomas Fork; Nils Karlsson; Sattar Kadhem; Bodil Ohlsson
Journal:  BMC Med Imaging       Date:  2012-02-15       Impact factor: 1.930

Review 3.  Imaging modalities for the noninvasive assessment of fibrosis in Crohn's disease.

Authors:  Cristina Stasi; Massimo Falchini; Stefano Milani
Journal:  ScientificWorldJournal       Date:  2012-04-30

Review 4.  The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response.

Authors:  Matthew P Moy; Jenny Sauk; Michael S Gee
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

Review 5.  Magnetic Resonance Imaging of the Small Bowel in Crohn's Disease: A Systematic Review and Meta-Analysis.

Authors:  Osman Ahmed; David Mario Rodrigues; Geoffrey C Nguyen
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-21

6.  Layered enhancement at magnetic resonance enterography in inflammatory bowel disease: A meta-analysis.

Authors:  Davide Bellini; Flaminia Rivosecchi; Nicola Panvini; Marco Rengo; Damiano Caruso; Iacopo Carbone; Riccardo Ferrari; Pasquale Paolantonio; Andrea Laghi
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.